Study guide
7.1 Parkinson's Disease & Movement Disorders
ABNN Certified Neuroscience Registered Nurse CNRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neuroanatomy, Physiology, and Neurological Assessment
1.1 Central & Peripheral Nervous System Anatomy 1.2 Cerebral Circulation, Blood-Brain Barrier & CSF Dynamics 1.3 Comprehensive Neurological Assessment & GCS 1.4 Cranial Nerve Examination & Localization
2 Chapter 2: Neurotrauma & Increased Intracranial Pressure
2.1 Traumatic Brain Injury Pathophysiology & Classification 2.2 Intracranial Pressure Dynamics, Monro-Kellie & Monitoring 2.3 Management of Increased ICP & Herniation Syndromes 2.4 Secondary Brain Injury Prevention & ICU Care
3 Chapter 3: Spinal Cord Injury & Neurotrauma Management
3.1 Spinal Cord Injury Pathophysiology & ASIA Classification 3.2 Spinal Shock vs. Neurogenic Shock Management 3.3 Autonomic Dysreflexia Recognition & Emergency Protocols 3.4 SCI Acute Nursing Care, Mobilization & Complications
4 Chapter 4: Cerebrovascular Disorders - Ischemic Stroke & Interventions
4.1 Ischemic Stroke Pathophysiology, Penumbra & Vascular Syndromes 4.2 Acute Ischemic Stroke Assessment & NIHSS 4.3 Thrombolytic Therapy (tPA/Alteplase/Tenecteplase) Protocols 4.4 Endovascular Thrombectomy & Post-Procedure Management
5 Chapter 5: Cerebrovascular Disorders - Hemorrhagic Stroke & Vascular Malformations
5.1 Intracerebral Hemorrhage Pathophysiology, ICH Score & Acute Management 5.2 Subarachnoid Hemorrhage, Aneurysm Clipping/Coiling & Hunt-Hess Grading 5.3 Cerebral Vasospasm & Delayed Cerebral Ischemia (DCI) Management 5.4 Arteriovenous Malformations (AVMs), Cavernomas & Dural AV Fistulas
6 Chapter 6: Neurological Disorders - Seizures & Epilepsy
6.1 Seizure Classification, Etiology & Pathophysiology 6.2 Status Epilepticus Emergency Protocols & Algorithm 6.3 Antiepileptic Drug (AED) Pharmacology & Monitoring 6.4 Surgical Interventions & Epilepsy Patient Education
7 Chapter 7: Movement & Demyelinating Disorders
7.1 Parkinson's Disease & Movement Disorders 7.2 Multiple Sclerosis & Demyelinating Conditions 7.3 Amyotrophic Lateral Sclerosis & Neuromuscular Junction Disorders 7.4 Dementias, Normal Pressure Hydrocephalus & Neuro Pain Syndromes
8 Chapter 8: Central Nervous System Tumors & Neuro-Oncology
8.1 Primary Brain Tumors: Gliomas, Meningiomas & Acoustic Neuromas 8.2 Metastatic CNS Disease & Epidural Spinal Cord Compression 8.3 Neuro-Oncology Therapies: Surgery, Radiation, Chemo & Immunotherapy 8.4 Oncologic Emergencies, Symptom Management & Palliative Priorities
9 Chapter 9: CNS Infections & Inflammatory Conditions
9.1 Bacterial, Viral & Fungal Meningitis 9.2 Encephalitis, Brain Abscess & Prion Diseases 9.3 Guillain-Barré Syndrome & Autoimmune Neurologic Conditions 9.4 Neuro-Infectious ICU Monitoring & Isolation Protocols
10 Chapter 10: Neurodevelopmental & Pediatric Conditions
10.1 Neural Tube Defects & Spina Bifida 10.2 Pediatric Hydrocephalus & Cranial Malformations 10.3 Cerebral Palsy & Developmental Neurologic Management
11 Chapter 11: Professional Practice & Special Considerations in Neuroscience Nursing
11.1 Ethical Considerations & End-of-Life Care in Neuro ICU 11.2 Patient & Family Education Across Neuro Conditions 11.3 Interdisciplinary Care Coordination & Rehabilitation Transitions 11.4 Quality Improvement, Research & Evidence-Based Practice
7.1 Parkinson's Disease & Movement Disorders
Key Takeaways Explain This Topic AI
Parkinson's disease is characterized by dopaminergic neuron loss in the substantia nigra, leading to profound dopamine depletion.
The TRAP acronym (Tremor, Rigidity, Akinesia, Postural instability) defines the core motor symptoms.
Levodopa/carbidopa is the primary treatment; it requires precise timing and protein management to avoid absorption issues.
Deep Brain Stimulation (DBS) is utilized for severe motor fluctuations and dyskinesias in advanced disease stages.
Last updated: July 2026
- Parkinson's Disease & Movement Disorders
- Pathophysiology of Parkinson's Disease
Parkinson's disease (PD) is a progressive, neurodegenerative movement disorder characterized by the profound loss of dopaminergic neurons, primarily located in the substantia nigra pars compacta of the basal ganglia. The basal ganglia are responsible for the smooth coordination and execution of voluntary motor movements. In a healthy neurological system, a delicate balance exists between dopamine (an inhibitory neurotransmitter) and acetylcholine (an excitatory neurotransmitter). When the substantia nigra undergoes dopamine depletion, this critical equilibrium is disrupted, leading to an overactivity of acetylcholine. This excessive excitatory signaling pathway results in the hallmark motor symptoms of the disease. The pathological hallmark of Parkinson's disease is the presence of Lewy bodies—intracytoplasmic inclusions composed largely of alpha-synuclein proteins—within the degenerating neurons. This progressive neurodegeneration extends beyond the basal ganglia, eventually affecting the cortex, brainstem, and peripheral autonomic nervous system, which accounts for the widespread non-motor symptoms associated with the condition. As the disease advances, the continued loss of dopaminergic pathways leads to severe motor fluctuations and increasingly complex clinical presentations that require advanced nursing management and multidisciplinary care.
Clinical Manifestations: The TRAP Assessment
The clinical diagnosis of Parkinson's disease relies heavily on the identification of specific motor deficits, commonly remembered by the TRAP acronym. Tremor is typically a "pill-rolling" resting tremor that is most prominent when the limb is fully supported and at rest. It often begins unilaterally and may decrease with purposeful movement or during sleep. Rigidity is characterized by increased resistance to passive movement of a joint throughout its entire range of motion. It may present as "cogwheel" rigidity (a jerky, ratchety resistance) or "lead-pipe" rigidity (a sustained, smooth resistance). Akinesia/Bradykinesia refers to the absence or slowness of movement. This is often the most disabling symptom, manifesting as a loss of spontaneous movements (e.g., decreased arm swing while walking, masked facies or hypomimia, decreased blink rate) and profound difficulty initiating voluntary movements. Postural instability is a later manifestation involving the loss of postural reflexes. Patients are highly susceptible to falls, typically falling backward (retropulsion) or forward (propulsion) due to an inability to correct their center of gravity. Furthermore, non-motor symptoms such as autonomic dysfunction, orthostatic hypotension, constipation, REM sleep behavior disorder, and cognitive impairment often precede motor symptoms and significantly impact the patient's quality of life, requiring astute nursing assessment.
Pharmacological Management
The cornerstone of Parkinson's disease management is pharmacological dopamine replacement and conservation. Nursing education regarding strict adherence to the medication schedule is paramount, as delayed doses can precipitate severe "off" periods where the patient becomes entirely immobile. Levodopa/carbidopa remains the gold standard therapy. Levodopa crosses the blood-brain barrier and is converted into dopamine. Carbidopa prevents the peripheral breakdown of levodopa, allowing a greater concentration to reach the CNS while minimizing peripheral side effects like profound nausea. A critical nursing consideration is that dietary proteins can compete with levodopa for absorption; therefore, it should be taken on an empty stomach or with a low-protein snack. Dopamine agonists directly stimulate postsynaptic dopamine receptors and are used early in the disease or as adjuncts. Nurses must monitor for severe side effects, including sudden sleep attacks, orthostatic hypotension, and impulse control disorders. MAO-B Inhibitors inhibit the breakdown of dopamine in the brain. Patients must be educated on the risk of serotonin syndrome if combined with certain antidepressants. COMT Inhibitors are solely used as adjuncts to levodopa to manage "wearing-off" periods, and may cause a benign orange-brown discoloration of urine. The precise administration and constant evaluation of these pharmacological agents form the bedrock of CNRN practice in movement disorders.
Surgical Interventions: Deep Brain Stimulation (DBS)
For patients who experience severe, intractable motor fluctuations or disabling dyskinesias despite optimized pharmacological therapy, surgical intervention may be indicated. Deep Brain Stimulation (DBS) involves the surgical implantation of electrodes into precise target areas of the brain—most commonly the subthalamic nucleus (STN) or the globus pallidus internus (GPi). These electrodes are connected to an implanted pulse generator (IPG) placed subcutaneously in the subclavicular space. DBS delivers high-frequency electrical stimulation that overrides abnormal neural firing patterns, significantly reducing tremor, rigidity, and bradykinesia, and allowing for a reduction in dopaminergic medication dosages. Postoperative nursing care focuses on rigorous neurological assessments, monitoring for intracranial hemorrhage, managing infection risks at the surgical sites, and assessing for device-related complications such as hardware malfunction or stimulation-induced side effects (e.g., dysarthria, paresthesia, muscle contractions). The nurse plays a critical role in educating the patient about living with a DBS device, including avoiding certain electromagnetic fields and understanding the programming process.
Nursing Care, Interventions, and Patient Education
Comprehensive nursing management of the Parkinson's disease patient is multifaceted and heavily prioritizes safety, mobility, and nutrition. Due to postural instability and bradykinesia, patients are at a critically high risk for falls. Nurses should educate patients to use a broad-based gait, consciously lift their feet to avoid the shuffling gait (festination), and use assistive devices as prescribed. "Freezing of gait" can be managed by teaching patients to step over imaginary lines on the floor or using rhythmic cues. Dysphagia is highly prevalent and can lead to silent aspiration and life-threatening aspiration pneumonia. Nursing interventions include collaborating with speech-language pathology, providing thickened liquids, ensuring the patient is seated upright at 90 degrees during and after meals, and monitoring weight. Exact timing of medications is non-negotiable. Nurses must meticulously coordinate medication administration with meal times and physical therapy sessions. Additionally, robust psychosocial support for both the patient and caregivers is vital due to the progressive nature of the disease and the high incidence of depression. Nurses must also be acutely aware of advanced directives and palliative care integration early in the disease process. As Parkinson's disease advances to Stage 4 and Stage 5 on the Hoehn and Yahr scale, the focus of care shifts intensely toward maximizing comfort, preventing skin breakdown due to immobility, and managing the severe neuropsychiatric complications such as Parkinson's disease dementia and visual hallucinations. Collaboration with a multidisciplinary team, including neurologists, physical therapists, occupational therapists, speech therapists, and social workers, is absolutely essential to provide holistic and effective care.
Hoehn and Yahr Scale Clinical Presentation
Stage 1 Unilateral involvement only, minimal or no functional impairment.
Stage 2 Bilateral or midline involvement, without impairment of balance.
Stage 3 First sign of impaired righting reflexes. Patient is physically independent.
Stage 4 Fully developed, severely disabling disease. Patient can still walk unassisted.
Stage 5 Confinement to bed or wheelchair unless aided.